Dr Van De Donk talks to ecancertv at ICMM 2016 about the results of phase II and III trials looking at drug combinations involving daratumumab for the treatment of myeloma patients.

He says that triple drug regimens will probably be the future but that biomarkers are still needed to see which patients will respond. 

For more on this, see the interview with Dr Plesner

ecancer's filming at ICMM 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content